- Home
- LDP vs IVA Comparison
LDP vs IVA Comparison
Compare LDP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
HOLD
Current Price
$3.72
Company Overview
Basic Information| Metric | LDP | IVA |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.9M | 737.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LDP | IVA |
|---|---|---|
| Price | $18.62 | $3.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.20 |
| AVG Volume (30 Days) | 109.4K | ★ 2.9M |
| Earning Date | 01-01-0001 | 09-28-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.63 | $2.82 |
| 52 Week High | $22.05 | $7.98 |
Technical Indicators
Market Signals| Indicator | LDP | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 56.06 |
| Support Level | N/A | $3.23 |
| Resistance Level | $20.93 | $3.76 |
| Average True Range (ATR) | 0.21 | 0.24 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 20.59 | 93.62 |
Price Performance
Historical Comparison LDP
IVA
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.